FDA Approves New Six Shots Per Year Eczema Maintenance Regimen

Dr. Rachel Mendez MD, Medical Science Writer

✨ Why this is good news

Atopic dermatitis is a chronic skin condition that causes itchy, inflamed skin, often requiring frequent injections to manage.

Only six shots per year.Before this approval, patients on Ebglyss needed injections every four weeks. Now the maintenance schedule drops to once every eight weeks, drastically cutting the annual number of shots and reducing the burden of frequent clinic visits.
New convenience over competitors.Existing treatments often require injections every two or four weeks. This new eight week interval for Ebglyss gives patients a less disruptive option, making it easier to stick with long term therapy and maintain clear skin.
FDA approved and specific to maintenance.The expanded label is tailored for the maintenance phase after initial treatment. This means patients who achieve control can now enjoy a much lighter dosing schedule, a targeted improvement that wasn’t available before.
Eli Lilly’s Ebglyss (lebrikizumab) now expanded.With this FDA approval, a new biologic joins the market with a unique dosing advantage. Patients with moderate-to-severe eczema now have a proven option that requires fewer injections over the course of a year, directly improving quality of life.

The U.S. Food and Drug Administration has approved a new maintenance dosing schedule for an eczema drug that could reduce injections to just six times per year, offering a significant convenience boost for patients with moderate-to-severe atopic dermatitis.

The expanded label for Eli Lilly’s Ebglyss (lebrikizumab) allows patients to receive a maintenance injection once every eight weeks after an initial induction period, rather than every four weeks. This change means patients need only six shots annually, a steep reduction from the every two or four week schedules required by current competing treatments such as Dupixent and Adbry. The approval is based on the Q8W Adjoin extension trial, which showed that the drug’s efficacy remained equivalent whether dosed every four or eight weeks.

Ebglyss works by selectively blocking interleukin-13, a key driver of inflammation in atopic dermatitis. Unlike some other treatments, the new label also does not require patients to use prescription topical therapies such as corticosteroids or calcineurin inhibitors from the start. The company highlighted that the dosing advantage, combined with strong safety data, could make the drug a leading option in a crowded market. Analysts have projected peak sales of up to $6 billion for the drug, which generated $408 million in revenue in 2025, its first full year on the U.S. market.

Expanding Access to Younger Patients

Alongside the maintenance approval, Lilly has released clinical trial data from March that could support expanding the drug’s label to children as young as six months old. Ebglyss is currently approved for adults and adolescents aged 12 and older. The company has not yet submitted a formal application for the younger age group, but the data marks a promising step toward broader access.

For patients living with moderate-to-severe eczema, the new option means fewer clinic visits and less disruption to daily life. As the company’s immunology president noted, the goal is to help patients “flare less and live their lives with fewer interruptions.” The drug was first approved in Europe in 2023 and later in the U.S., Japan, and Canada in 2024. With this latest label expansion, Ebglyss positions itself as a long-term, low burden therapy for a chronic condition that affects millions worldwide.

This article is for informational purposes only and does not constitute medical advice. The information presented is based on published research and official announcements. Always consult a qualified healthcare professional before making any medical decisions.